Cure­Vac to de­vel­op mR­NA-based flu, malar­ia vac­cines with new Gates Foun­da­tion grants

With a fresh round of fund­ing from the Bill and Melin­da Gates Foun­da­tion, Cure­Vac is gear­ing up its mes­sen­ger RNA plat­form to de­vel­op mR­NA-based vac­cines for in­fluen­za and malar­ia in­fec­tion. In par­tic­u­lar, the part­ners will shoot for a uni­ver­sal flu vac­cine, an in­creas­ing­ly pop­u­lar re­search field giv­en the eva­sive na­ture of the in­fluen­za A virus.

The two new grants build up­on a col­lab­o­ra­tion that dates back to 2015, when the Gates Foun­da­tion made a $52 mil­lion eq­ui­ty in­vest­ment in Cure­Vac to sup­port its tech plat­form and help con­struct a pro­duc­tion fa­cil­i­ty. De­tails about the grants were not dis­closed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER